These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3526129)

  • 41. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 42. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Lowering cholesterol. New concepts with atorvastatin].
    Internist (Berl); 1997 Jan; 38(1 Suppl):1-8. PubMed ID: 9102396
    [No Abstract]   [Full Text] [Related]  

  • 44. [Study of metabolic and clinical effects of polyunsaturated fatty acids omega-3 from "Eicovit" in patients with ischemic heart disease and familial hyperlipoproteinemia].
    Sorokovoĭ KV; Pogozheva AV; Kulakova SN; Lupinovich VL; Karagodina ZV; Levachev MM; Samsonov MA; Vorsanovich EA
    Vopr Pitan; 1998; (2):29-31. PubMed ID: 9680669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Evaluation of the effect of hypolipemic drugs in atherosclerosis].
    Beaumont JL
    Nouv Presse Med; 1980 Oct; 9(40):2945-6. PubMed ID: 7443427
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 47. Pantethine versus fenofibrate in the treatment of type II hyperlipoproteinemia.
    Postiglione A; Rubba P; Cicerano U; Chierchia I; Mancini M
    Monogr Atheroscler; 1985; 13():145-8. PubMed ID: 3911056
    [No Abstract]   [Full Text] [Related]  

  • 48. [1,5-dicoffeechinic acid in the treatment of hypertriglyceridemia].
    Wojcicki J; Olejak B; Pieczul-Mróz J; Torbus-Lisiecka B; Bukowska H; Gregorczyk J
    Przegl Lek; 1982; 39(9):601-6. PubMed ID: 6897455
    [No Abstract]   [Full Text] [Related]  

  • 49. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
    Sznajderman M; Zawadzki Z
    Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
    [No Abstract]   [Full Text] [Related]  

  • 50. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Regression of arteriosclerosis. Results of animal experiments and human medical studies, results of drug therapy].
    Kaffarnik H; Zehner J
    Fortschr Med; 1985 May; 103(20):531-4. PubMed ID: 4007752
    [No Abstract]   [Full Text] [Related]  

  • 52. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 55. [Subfractions of HDL cholesterol. Occurrence in hyperlipoproteinemia type IIa and IV].
    Mertz DP; Thuilot G; Bürvenich K
    Fortschr Med; 1986 Jul; 104(26):508-10. PubMed ID: 3744260
    [No Abstract]   [Full Text] [Related]  

  • 56. [The characteristics of the hypolipidemic effect of Mevacor with its permanent multiyear use].
    Lipovetskiĭ BM
    Ter Arkh; 1996; 68(12):72-5. PubMed ID: 9054048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Correction of dyslipoproteinemia in middle-aged and elderly patients with atherosclerosis using Essentiale in combination with adebit].
    Korkushko OV; Bogatskaia LN; Kovalenko AN; Novikova SN; Kotko DN
    Vrach Delo; 1989 Aug; (8):19-22. PubMed ID: 2588515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Results of prevention trials by intervention with lipids].
    Turpin G
    Arch Mal Coeur Vaiss; 1987 Apr; 80 Spec No():37-42. PubMed ID: 3113396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of the administration of silymarin on serum lipid levels].
    Petronelli A; Roda E; Briganti M; Morselli Labate AM; Barbara L
    Clin Ter; 1981 Dec; 99(5):471-82. PubMed ID: 7333068
    [No Abstract]   [Full Text] [Related]  

  • 60. [Fibrinolytic capacity after exertion in atherogenic hyperlipoproteinemias].
    Zdrenghea D; Mărcuşu C; Cucuianu M; Rentsch S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):435-40. PubMed ID: 44567
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.